Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søk Study Connect
  • NCT06122779

Recruiting

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) - CV029-1001

Oppdatert: 13 januar, 2025   |   ClinicalTrials.gov

Utskriftsvennlig Sammendrag

VURDERER DU DENNE STUDIEN?
Skriv ut denne siden og studieveiledningen for å hjelpe deg å snakke med legen din.
Bruk Veiledning for studiedeltakere til å navigere gjennom deltakerprosessen i en klinisk studie. Forstå viktige faktorer å vurdere før du bestemmer deg og motta spørsmål som du kan stille til helsepersonalet ditt.
Skriv ut denne siden CV029-1001
Last ned Veiledning for studiedeltakere

VELG SPRÅK

Vis detaljer

  • Phase 2

    Fase

  • Kjønn

  • 40-90

    Aldersgruppe

  • 16

    Sted(er)

  • Recruiting

Behandlingsalternativer

Studiearmer
TILDELT INTERVENSJON
Experimental: BMS-986435
Drug: BMS-986435
Placebo Comparator: Placebo
Other: Placebo

Nøkkelkriterier for kvalifikasjon

Key Inclusion Criteria: - Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability Key Exclusion Criteria: - Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant Note: Other protocol-defined inclusion/exclusion criteria apply

Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon

MLTNO2000046